This observation was further verified by the use of mutant IGF-1, which is defective in integrin-IGF-1R tertiary complex formation, can suppress IGF-1-mediated tumorigenesis in vivo in breast cancer and skin squamous cell carcinoma (Fujita et al., 2013; Takada et al., 2017). This evidence concerns the gene IGF1 and breast cancer.